Organovo Presents Data on Creating Stem Cell-Based Bioprinted Kidney Organoids at the International Society for Stem Cell Res...
July 08 2019 - 7:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology
company pioneering the development of 3D bioprinted tissues aimed
at treating a range of serious diseases, presented data on
fabricating stem cell-based kidney tissues at The International
Society for Stem Cell Research 2019 Annual Meeting held in Los
Angeles, Ca. from June 26-29, 2019.
Organovo has continued to adapt stem-cell based approaches to
developing kidney tissues using its leading 3D bioprinting
platform. The Company has demonstrated the automated
production of complex kidney organoids, with potential future
applications including in vitro disease modeling and the treatment
of patients with renal disease.
“Partnerships with world-class institutions can accelerate
groundbreaking work in finding cures for critical unmet disease
needs and the development of implantable therapeutic tissues,”
said Taylor J. Crouch, CEO, Organovo. “Our recently
announced collaboration with Murdoch Children’s Research Institute
(“MCRI”) and Professor Melissa Little has made our work automating
the fabrication of kidney organoids possible. By combining
MCRI’s proprietary approach for modeling human kidney tissue from
stem cells and Organovo’s 3D bioprinting platform, we’re able to
produce detailed kidney tissues, which is a key step toward
advancing this promising technology for both drug testing and
therapeutic applications. We’re hopeful that this will be an
important step along the way in treating kidney disease.”
The Company’s poster is as follows:
Title:
Bioprinted Pluripotent Stem Cell-Derived Kidney Organoids Provide
Opportunities for High Content Screening
Poster:
T-4013
https://organovo.com/bioprinted-pluripotent-stem-cell-derived-kidney-organoids-provide-opportunities-for-high-content-screening-2/
About Organovo Holdings, Inc.Organovo is a
biotech platform company that has developed a leadership position
with its revolutionary ability to 3D bioprint tissues with human
functionality. The Company is pursuing IND-track programs to
develop its NovoTissues® to address a number of serious unmet
medical needs, initially focusing on liver disease.
Organovo’s program for Alpha-1-antitrypsin deficiency received
orphan drug designation from the FDA in 2017. The Company is
also providing access to its ExVive™ in vitro tissue platform to
facilitate high value drug discovery and development
collaborations. Organovo’s wholly-owned subsidiary, Samsara
Sciences, provides the Company and its clients with high quality
human liver cells for research applications. Organovo is
changing the shape of life science research and transforming
medical care. Learn more at www.organovo.com.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are
not limited to, statements regarding the potential benefits and
therapeutic uses of the Company’s therapeutic liver and kidney
tissues, including the benefits of an orphan designation; the
Company’s expectations regarding the FDA regulatory pathway and
anticipated timelines for its regulatory filings; the Company’s
ability to successfully complete additional preclinical studies,
improve its manufacturing processes and demonstrate the prolonged
functionality and therapeutic benefits of its therapeutic liver
tissue; the Company’s ability to implement clinical scale
manufacturing and quality processes; the Company’s ability to meet
market demand; the Company’s ability to fund its future operations
and business plans; and acceptance of its disease modeling and
other in vitro tissue platforms. The factors that could cause
the Company's actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the possibility that the final results of
the Company's earlier preclinical studies may be different from the
Company's later preclinical studies and may not support further
clinical development of its therapeutic tissues, or that the
results of the Company’s preclinical studies may be different from
the results of its clinical trials; the Company may not
successfully complete the required preclinical and clinical trials
required to obtain regulatory approval for its therapeutic tissues
on a timely basis or at all; the novelty of the therapeutic
approach and risks relating to its adoption rate by clinicians; the
complexity of the manufacturing process and the effort involved in
developing GTP and GMP facilities; the nascence of the industry and
the lack of experienced GMP manufacturing organizations for
bioprinting tissues; risks relating to the Company’s ability to
successfully scale up from research to clinical tissue patches;
risks relating to the Company’s reliance on a single supplier for
clinical grade organs, including that the Company may not be able
to obtain sufficient raw materials to meet clinical or commercial
demand for its therapeutic products; risks that competitive
products may adversely impact the market opportunity for the
Company’s therapeutic tissue candidates; the Company's ability to
develop, market and sell products and services based on its
technology; the expected benefits and efficacy of the Company's
products, services and technology; the Company’s ability to
successfully complete studies and provide the technical information
required to support market acceptance of its disease modeling and
other in vitro tissue products, services and technology, on a
timely basis or at all; the Company’s ability to raise sufficient
funds to support its business plan and ongoing operations; the
Company’s ability to regain compliance with the NASDAQ Global
Market’s listing requirements and ability to remain listed on the
NASDAQ Global Market exchange; the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies, including its use of third party
distributors; and the Company’s ability to recognize deferred
revenue. These and other factors are identified and described
in more detail in the Company's filings with the SEC, including its
Annual Report on Form 10-K filed with the SEC on June 3, 2019. You
should not place undue reliance on these forward-looking
statements, which speak only as of the date that they were made.
These cautionary statements should be considered with any written
or oral forward-looking statements that the Company may issue in
the future. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to reflect actual results, later events or circumstances
or to reflect the occurrence of unanticipated events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2023 to Oct 2024